CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID (ZA)

Abstract Objective To determine the risk factors for herpes zoster (HZ) in patients with rheumatic diseases in Korea. Methods We used the nationwide database of the Health Insurance Review & Assessment Service to analyse patients aged ≥20 years who had visited a hospital more than twice for rheumatic disease as a principal diagnosis from January 2009 to April 2013. HZ was identified using HZ-related Korean Standard Classification of Diseases 6 (KCD-6) codes and the prescription of antiviral agents. The relationship between demographics, comorbidities and medications and HZ risk was analysed by Cox proportional hazards models. Results HZ developed in 1869 patients. In Cox proportional hazards models, female sex but not age showed an increased adjusted hazard ratio (HR) for HZ. Comorbidities such as haematologic malignancies, hypertension, diabetes mellitus, and chronic lung and liver diseases led to an increased HR. HZ risk was higher in patients with SLE (HR: 4.29, 95% CI: 3.49, 5.27) and Behçet’s syndrome (BS, HR: 4.54; 95% CI: 3.66, 5.64) than with RA. The use of conventional DMARDs, immunosuppressants, TNF inhibitors, glucocorticoids and NSAIDs increased the HR. Infliximab and glucocorticoids (equivalent prednisolone dose >15 mg/day) produced the highest HZ risk (HR: 2.91, 95% CI: 1.72, 4.89; HR: 2.85, 95% CI: 2.15, 3.77, respectively). Conclusion Female sex, comorbidities and medications increased HZ risk in patients with rheumatic diseases and even young patients could develop HZ. Compared with RA, SLE and BS are stronger HZ risk factors. Patients with rheumatic diseases and these risk factors are potential target populations for HZ vaccination.

Download Full-text

Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.4630 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 4630-4630 ◽

Cited By ~ 3

Author(s):

D. J. Sleep ◽

J. B. Nelson ◽

D. P. Petrylak ◽

J. D. Isaacson ◽

M. A. Carducci

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Disease Progression ◽

Proportional Hazards ◽

Cord Compression ◽

Cox Proportional Hazards ◽

Hormone Refractory Prostate Cancer ◽

Double Blind ◽

The Difference ◽

Hormone Refractory

4630 Background: Hormone-refractory prostate cancer (HRPC) metastasizes most commonly to bone. Treatment of advanced HRPC patients focuses on alleviating bone pain that afflicts 85% of patients. New therapies are needed that not only prolong survival but slow the progression of morbidity. Atrasentan, a selective endothelin A receptor antagonist that blocks the effect of endothelin in the bone microenvironment by slowing osteoblast proliferation, may slow disease progression in HRPC patients with bone metastases. Methods: Patients enrolled in a randomized, double-blind, placebo-controlled multinational trial of atrasentan 10 mg with independently confirmed bone metastases (N = 690) were followed until the first event of disease progression, which could be by radiographic (≥2 new lesions on bone scan) or clinical means (eg, pain requiring significant opioids or other interventions, spinal cord compression). Analyses were performed on time to disease progression and separately on time to clinical and radiographic progression. The difference between treatments was analyzed using Kaplan-Meier methods and Cox proportional hazards modeling. Results: N = 335 for placebo; N = 355 for atrasentan. Atrasentan therapy resulted in fewer disease progression events relative to placebo and reduced the risk of disease progression by 19% ( Table ). The differential effect of atrasentan on disease progression was most notable against clinical progression (32% reduction in risk vs placebo). Conclusions: In men with HRPC metastatic to bone, atrasentan delays disease progression, especially clinical events, relative to placebo. [Table: see text] [Table: see text]

Download Full-text

Indigeneity, Prisoner Visitation and Reincarceration in Australia: The Association Between Visits in Prison and Reincarceration for Indigenous and Non-Indigenous People

The British Journal of Criminology ◽

10.1093/bjc/azaa009 ◽

2020 ◽

Vol 60 (4) ◽

pp. 1056-1079

Author(s):

Nicole Ryan ◽

Jeff Ackerman ◽

Justin Ready ◽

Stuart A Kinner

Keyword(s):

Logistic Regression ◽

Criminal Justice ◽

Indigenous People ◽

Administrative Data ◽

Proportional Hazards ◽

Cox Proportional Hazards ◽

Travel Distance ◽

Proportional Hazards Models ◽

Cox Proportional Hazards Models ◽

Criminal Justice Systems

Abstract Prison visitation is believed to protect against reincarceration post-release. This research explored differences in prisoner visitation between Indigenous and non-Indigenous people, the predictors of visitation and the effects of visitation on the risk of reincarceration. Descriptive analyses, logistic regression and Cox proportional hazards models were conducted using survey and linked administrative data for 1,238 Australian prisoners. We found that Indigenous people compared to non-Indigenous people were less likely to be visited, and travel distance decreased the likelihood of visitation for both groups. Moreover, visitation protected against reincarceration for non-Indigenous people only. Potential explanations for why visitation was not found to protect against reincarceration for Indigenous people are discussed as are potential implications for criminal justice systems that house Indigenous offenders.

Download Full-text

810 ORAL Risk and risk factors of renal impairment in hormone refractory prostate cancer (HPRC) patients with bone metastases (BM) treated with Zoledronic Acid (ZA)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)81105-x ◽

2005 ◽

Vol 3 (2) ◽

pp. 231-232 ◽

Cited By ~ 1

Keyword(s):

Prostate Cancer ◽

Risk Factors ◽

Zoledronic Acid ◽

Renal Impairment ◽

Bone Metastases ◽

Hormone Refractory Prostate Cancer ◽

Hormone Refractory

Download Full-text

A Comparison of the Polytomous Logistic Regression and Joint Cox Proportional Hazards Models for Evaluating Multiple Disease Subtypes in Prospective Cohort Studies

Cancer Epidemiology Biomarkers & Prevention ◽

10.1158/1055-9965.epi-12-1050 ◽

2013 ◽

Vol 22 (2) ◽

pp. 275-285 ◽

Cited By ~ 32

Author(s):

Xiaonan Xue ◽

Mimi Y. Kim ◽

Mia M. Gaudet ◽

Yikyung Park ◽

Moonseong Heo ◽

...

Keyword(s):

Logistic Regression ◽

Cohort Studies ◽

Prospective Cohort ◽

Proportional Hazards ◽

Cox Proportional Hazards ◽

Proportional Hazards Models ◽

Prospective Cohort Studies ◽

Cox Proportional Hazards Models ◽

Disease Subtypes ◽

Polytomous Logistic Regression

Download Full-text

The Longitudinal Association of Vision Impairment with Transitions to Cognitive Impairment and Dementia: Findings from The Aging, Demographics and Memory Study

The Journals of Gerontology Series A ◽

10.1093/gerona/glab157 ◽

2021 ◽

Author(s):

Joshua R Ehrlich ◽

Bonnielin K Swenor ◽

Yunshu Zhou ◽

Kenneth M Langa

Keyword(s):

Visual Acuity ◽

Logistic Regression ◽

Cognitive Impairment ◽

Proportional Hazards ◽

Population Based ◽

Cox Proportional Hazards ◽

Vision Impairment ◽

Logistic Regression Models ◽

Cox Proportional Hazards Models ◽

Longitudinal Association

Abstract Background Vision impairment (VI) is associated with incident cognitive decline and dementia. However, it is not known whether VI is associated only with the transition to cognitive impairment, or whether it is also associated with later transitions to dementia. Methods We used data from the population-based Aging, Demographics and Memory Study (ADAMS) to investigate the association of visual acuity impairment (VI; defined as binocular presenting visual acuity <20/40) with transitions from cognitively normal (CN) to cognitive impairment no dementia (CIND) and from CIND to dementia. Multivariable Cox proportional hazards models and logistic regression were used to model the association of VI with cognitive transitions, adjusted for covariates. Results There were 351 participants included in this study (weighted percentages: 45% male, 64% age 70-79 years) with a mean follow-up time of 4.1 years. In a multivariable model, the hazard of dementia was elevated among those with VI (HR=1.63, 95%CI=1.04-2.58). Participants with VI had a greater hazard of transitioning from CN to CIND (HR=1.86, 95%CI=1.09-3.18). However, among those with CIND and VI a similar percentage transitioned to dementia (48%) and remained CIND (52%); there was no significant association between VI and transitioning from CIND to dementia (HR=0.94, 95%CI=0.56-1.55). Using logistic regression models, the same associations between VI and cognitive transitions were identified. Conclusions Poor vision is associated with the development of CIND. The association of VI and dementia appears to be due to the higher risk of dementia among individuals with CIND. Findings may inform the design of future interventional studies.

Download Full-text

Abstract P030: Variations in Cardiovascular Risk Among Different Clinical Presentations of Metabolic Syndrome in the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study

Circulation ◽

10.1161/circ.125.suppl_10.ap030 ◽

2012 ◽

Vol 125 (suppl_10) ◽

Author(s):

Todd M Brown ◽

Joshua Richman ◽

Vera Bittner ◽

Cora E Lewis ◽

Jenifer Voeks ◽

...

Keyword(s):

Risk Factors ◽

Metabolic Syndrome ◽

Racial Differences ◽

Central Obesity ◽

Proportional Hazards ◽

Cox Proportional Hazards ◽

Next Of Kin ◽

Cox Proportional Hazards Models ◽

Chd Risk ◽

The Individual

Background: Some individuals classified as having metabolic syndrome (MetSyn) are centrally obese while others are not with unclear implications for cardiovascular (CV) risk. Methods: REGARDS is following 30,239 individuals ≥45 years of age living in 48 states recruited from 2003-7. MetSyn risk factors were defined using the AHA/NHLBI/IDF harmonized criteria with central obesity being defined as ≥88 cm in women and ≥102 cm in men. Participants with and without central obesity were stratified by whether they met >2 or ≤2 of the other 4 MetSyn criteria, resulting in the creation of 4 groups. To ascertain CV events, participants are telephoned every 6 months with expert adjudication of potential events following national consensus recommendations and based on medical records, death certificates, and interviews with next-of-kin or proxies. Acute coronary heart disease (CHD) was defined as definite or probable myocardial infarction or acute CHD death. To determine the association between these 4 groups and incident acute CHD, we constructed Cox proportional hazards models in those free of CHD at baseline by race/gender group, adjusting for sociodemographic variables. Results: A total of 20,018 individuals with complete data on MetSyn components were free of baseline CHD. Mean age was 64+/−9 years, 58% were women, and 42% were African American. Over a mean follow-up of 3.4 (maximum 5.9) years, there were 442 acute CHD events. In the non-centrally obese with>2 other risk factors, risk for CHD was higher for all but AA men, though significant only for white men. In contrast, in the centrally obese with >2 other risk factors, risk was doubled for women, but only non-significantly and modestly increased for men. Only AA women with central obesity and ≤2 other risk factors had increased CHD risk (Table). Conclusion: The CHD risk associated with the MetSyn varies by the presence of central obesity as well as the race and gender of the individual.

Download Full-text